idiopathic pulmonary fibrosis

Showing 12 posts of 12 posts found.

Boehringer Ingelheim says Phase III trials for its Ofev slowed progression of fatal lung disease

June 27, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, drug trial, idiopathic pulmonary fibrosis, research

German drugmaker Boehringer Ingelheim said late-stage trials for its Ofev (nintedanib) to treat a fatal lung condition slowed progression of …

boehringer_good

Boehringer launches IPF initiatives

February 29, 2016
Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev

Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …

Gilead logo

Gilead terminates Phase II simtuzumab IPF study

January 6, 2016
Research and Development Gilead, IPF, idiopathic pulmonary fibrosis, simtuzumab

Gilead Sciences has announced the termination of its Phase II clinical study of the investigational monoclonal antibody simtuzumab in patients …

Roche says Esbriet shown to extend lives of IPF patients

September 30, 2015
Medical Communications, Research and Development, Sales and Marketing Esbriet, Roche, idiopathic pulmonary fibrosis

Roche has presented new clinical data and abstracts on Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF), showing …

Esbriet

Roche to present new Esbriet data at ERS Congress 2015

September 21, 2015
Research and Development, Sales and Marketing Esbriet, European Respiratory Congress, Roche, idiopathic pulmonary fibrosis, pirfenidone

Roche has announced it will present new data analyses of Esbriet in idiopathic pulmonary fibrosis (IPF) at the European Respiratory …

ofev1

Boehringer earns NICE nod for IPF drug Ofev

September 14, 2015
Sales and Marketing Boehringer Ingelheim, IPF, NICE, idiopathic pulmonary fibrosis

NICE has recommended Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis after the German firm agreed to a …

Bristol-Myers Squibb makes big pharma deals

September 1, 2015
Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis

Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …

ERS event image

InterMune’s IPF drug shines at ERS Congress

September 10, 2014
Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, IPF, InterMune, idiopathic pulmonary fibrosis, munich, pirfenidone

InterMune has posted positive data for its lung-scarring drug at this year’s European Respiratory Society Annual Congress 2014 (ERS). Pharmafile …

Boehringer and InterMune data on IPF drugs impress

May 19, 2014
Research and Development, Sales and Marketing Boehringer Ingelheim, InterMune, idiopathic pulmonary fibrosis

Two new medicines for a generally fatal lung disease, known as idiopathic pulmonary fibrosis and made by Boehringer and InterMune, …

First idiopathic pulmonary fibrosis drug approved

March 4, 2011
Sales and Marketing Esbriet, IPF, InterMune, Orphan Drugs, idiopathic pulmonary fibrosis, orphan drug

The first ever treatment for the potentially fatal lung disease idiopathic pulmonary fibrosis (IPF) has been approved in the EU. …

Gilead set to acquire Arresto for $225 million

December 23, 2010
Research and Development AB0024, Arresto, Cancer, Gilead, advanced solid tumours, ambrisentan, fibrotic diseases, idiopathic pulmonary fibrosis

Gilead Sciences is set to acquire fellow California, US-based biotech Arresto for $225 million to bolster its early stage pipeline. …

Latest content